NICE recommends Invokana for Type 2 Diabetes treatment - Janssen
The National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination recommending Invokana (canagliflozin) from Janssen Pharmaceuticals to reduce blood sugar levels in Type 2 Diabetic patients unable to achieve adequate control via diet and lifestyle changes or treatment with other products. The full guidance for Invokana covers its use as a treatment for adults with Type 2 Diabetes if used in combination with metformin when a sulfonylurea, such as glimepiride, is contraindicated or not tolerated, or where the person is at significant risk of hypoglycaemia. It can also be used as part of a triple therapy combination along with metformin and a sulfonylurea, or metformin and thiazolidinedione, or in combination with insulin with or without another diabetes treatment.
NICE has already approved Forxiga (dapagliflozin) AstraZeneca in the same class.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.